NASDAQ:XENE

Xenon Pharmaceuticals (XENE) Stock Forecast, Price & News

$35.17

-0.59 (-1.65%)

(As of 09/22/2023 ET)

Compare

Today's Range: $35.05
▼
$36.03
50-Day Range: $35.07
▼
$39.73
52-Week Range: $31.79
▼
$43.75

Volume: 267,832 shs
Average Volume: 368,663 shs
Market Capitalization: $2.26 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $52.40

Xenon Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.09 Rating Score
Upside/Downside: 49.0% Upside
$52.40 Price Target
Short Interest: Bearish
4.33% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.62
Based on 7 Articles This Week
Insider Trading: Selling Shares
$967,500 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.89) to ($3.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

490th out of 968 stocks

Pharmaceutical Preparations Industry

213th out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Xenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $52.40, Xenon Pharmaceuticals has a forecasted upside of 49.0% from its current price of $35.17.
Amount of Analyst Coverage
Xenon Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.33% of the outstanding shares of Xenon Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in Xenon Pharmaceuticals has recently increased by 2.21%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Xenon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Xenon Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for XENE.

3.1

News and Social Media Coverage

News Sentiment
Xenon Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Xenon Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for XENE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
4 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $967,500.00 in company stock.
Percentage Held by Insiders
Only 5.43% of the stock of Xenon Pharmaceuticals is held by insiders.
Percentage Held by Institutions
95.70% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($2.89) to ($3.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xenon Pharmaceuticals is -14.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xenon Pharmaceuticals is -14.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Xenon Pharmaceuticals has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE Price History

30 days | 90 days | 365 days | Advanced Chart

XENE Stock News Headlines

September 21, 2023 | americanbankingnews.com

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)

September 20, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: GoHealth (GOCO) and Xenon (XENE)

September 22, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 16, 2023 | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to Sell

September 14, 2023 | finance.yahoo.com

Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

September 12, 2023 | finance.yahoo.com

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

September 12, 2023 | finance.yahoo.com

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

September 4, 2023 | finance.yahoo.com

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

September 22, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

August 31, 2023 | finance.yahoo.com

Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference

August 22, 2023 | nasdaq.com

Cantor Fitzgerald Reiterates Xenon Pharmaceuticals (XENE) Overweight Recommendation

August 13, 2023 | msn.com

Xenon Is Well-Funded Heading Into Key Readouts

August 11, 2023 | finance.yahoo.com

Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade

August 11, 2023 | finanznachrichten.de

Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 11, 2023 | msn.com

Wedbush Reiterates Xenon Pharmaceuticals (XENE) Outperform Recommendation

August 9, 2023 | finance.yahoo.com

Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023 | finance.yahoo.com

Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth

August 8, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Xenon Pharmaceuticals's earnings

August 8, 2023 | financialpost.com

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

August 3, 2023 | finance.yahoo.com

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update

July 23, 2023 | finance.yahoo.com

11 Best Healthcare Stocks Under $50

July 17, 2023 | msn.com

RBC Capital Reiterates Xenon Pharmaceuticals (XENE) Outperform Recommendation

July 17, 2023 | markets.businessinsider.com

Expert Ratings for Xenon Pharmaceuticals

June 15, 2023 | markets.businessinsider.com

Guggenheim Sticks to Their Buy Rating for Xenon (XENE)

June 6, 2023 | finance.yahoo.com

Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

May 31, 2023 | finance.yahoo.com

Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference

May 30, 2023 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on Xenon (XENE)

See More Headlines

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Company Calendar

Last Earnings: 8/09/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XENE
CUSIP: N/A
CIK: 1582313
Web: www.xenon-pharma.com
Phone: (604) 484-3300
Fax: 604-484-3450
Employees: 203
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $52.40
High Stock Price Forecast: $60.00
Low Stock Price Forecast: $47.00
Forecasted Upside/Downside: +49.0%
Consensus Rating: Buy
Rating Score (0-4): 3.09
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-125,370,000.00
Net Margins: N/A
Pretax Margin: -123,568.95%
Return on Equity: -23.32%
Return on Assets: -22.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.34
Quick Ratio: 19.34

Sales & Book Value

Annual Sales: $9.43 million
Price / Sales: 239.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.54 per share
Price / Book: 3.05

Miscellaneous

Outstanding Shares: 64,150,000
Free Float: 60,663,000
Market Cap: $2.26 billion
Optionable: Optionable
Beta: 1.34

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Ian C. Mortimer C.M.A. (Age 47)
CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director
Comp: $973.76k

Ms. Sherry Aulin (Age 40)
Chief Financial Officer
Comp: $3.03M

Ms. Andrea DiFabio J.D. (Age 55)
Chief Legal Officer & Corp. Sec.
Comp: $200.51k

Dr. Christopher E. Von Seggern M.B.A. (Age 44)
M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
Comp: $618.07k

Dr. Christopher John Kenney M.D. (Age 52)
Chief Medical Officer
Comp: $684.22k

Ms. Shelley McCloskey B.A. (Age 63)
Exec. VP of HR

Dr. Robin P. Sherrington Ph.D. (Age 62)
Exec. VP of Strategy & Innovation

Dr. James R. Empfield Ph.D. (Age 62)
Exec. VP of Drug Discovery

Ms. Sheila M. Grant M.B.A.
M.Sc., MBA, Exec. VP of R&D Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XENE Stock - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XENE shares.
View XENE analyst ratings or view top-rated stocks.
What is Xenon Pharmaceuticals' stock price forecast for 2023?: 11 Wall Street analysts have issued twelve-month price objectives for Xenon Pharmaceuticals' shares. Their XENE share price forecasts range from $47.00 to $60.00. On average, they expect the company's stock price to reach $52.40 in the next year. This suggests a possible upside of 49.0% from the stock's current price.
View analysts price targets for XENE or view top-rated stocks among Wall Street analysts.
How have XENE shares performed in 2023?: Xenon Pharmaceuticals' stock was trading at $39.43 at the beginning of 2023. Since then, XENE stock has decreased by 10.8% and is now trading at $35.17.
View the best growth stocks for 2023 here.
When is Xenon Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our XENE earnings forecast.
How were Xenon Pharmaceuticals' earnings last quarter?: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.03. Xenon Pharmaceuticals's revenue was down 100.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.55) EPS.
What ETFs hold Xenon Pharmaceuticals' stock?: ETFs with the largest weight of Xenon Pharmaceuticals (NASDAQ:XENE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO) and BNY Mellon Innovators ETF (BKIV).First Trust Multi-Manager Small Cap Opportunities ETF (MMSC).

What other stocks do shareholders of Xenon Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).
What is Xenon Pharmaceuticals' stock symbol?: Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
Who are Xenon Pharmaceuticals' major shareholders?: Xenon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Driehaus Capital Management LLC (7.42%), Polar Capital Holdings Plc (4.71%), Braidwell LP (2.85%), Perceptive Advisors LLC (1.91%), BlackRock Inc. (1.56%) and Nicholas Investment Partners LP (1.24%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends.
How do I buy shares of Xenon Pharmaceuticals?: Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Xenon Pharmaceuticals' stock price today?: One share of XENE stock can currently be purchased for approximately $35.17.
How much money does Xenon Pharmaceuticals make?: Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.26 billion and generates $9.43 million in revenue each year. The biopharmaceutical company earns $-125,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis.
How many employees does Xenon Pharmaceuticals have?: The company employs 203 workers across the globe.
How can I contact Xenon Pharmaceuticals?: Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.

This page (NASDAQ:XENE) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial